2021 Top Story in Prostate Cancer: An Inflection Point — The Dawn of PSMA Theranostics
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385(12):1091-1103
- Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.